A practical course on hypertension thresholds, treatment targets, 2025 guideline updates,
prevention, risk assessment, and patient-centered interpretation across major guideline bodies.
Course progress0%
Start Here
What learners will be able to do
Learner registration
Enter the learner's information before starting. Results are stored in this browser and can be exported for upload to a roster or LMS.
Explain the evolution
Describe how hypertension moved from a high-threshold, diastolic-focused diagnosis to risk-based, lower-target management.
Compare guideline bodies
Recognize why ACC/AHA, ESC/ESH, WHO/ISH, and NICE do not always use the same diagnostic and treatment thresholds.
Apply 2025 updates
Use newer guidance on lower targets, earlier therapy, PREVENT risk, albuminuria testing, aldosteronism screening, sodium, weight, and alcohol.
Source basis: This course is adapted for education from a 2026 historical review of blood pressure thresholds and targets
and a 2025 JAMA Medical News summary of new blood pressure guideline updates. It is educational only and is not a diagnostic device,
treatment order, or substitute for clinician judgment, local protocol, or the full source guidelines.
1HistoryFrom DBP-heavy diagnosis to systolic, risk-based targets.
2GuidelinesWhere major societies agree and where they diverge.
32025 updateLower goals, earlier therapy, combination treatment, and PREVENT.
4WorkupMeasurement, albuminuria, primary aldosteronism, CKD, diabetes, and risk.
5CounselingSodium, potassium salt substitutes, weight loss, alcohol, and shared decisions.
Module 1
Why blood pressure thresholds changed
Earlier hypertension management focused on very high pressure values, especially diastolic blood pressure.
Over time, evidence linked lower pressure ranges to cardiovascular, kidney, and brain outcomes, so guideline
definitions, treatment thresholds, and treatment targets moved downward.
Before formal guidelines, hypertension was often treated as a sign of another condition rather than an independent risk factor.
Early guideline eras relied heavily on diastolic blood pressure, often using DBP thresholds near 90 to 100 mm Hg.
Later guidance incorporated systolic blood pressure, cardiovascular risk, diabetes, CKD, organ damage, and global risk calculators.
Modern controversy comes from balancing earlier prevention against treatment burden, cost, adverse effects, and real-world feasibility.
Five broad phases
Pre-guideline: high values and symptomatic disease.
1977-1992: formal targets, DBP emphasis.
1993-2004: 140/90 era plus risk categories.
2005-2017: relative stability and some less stringent targets.
2017-2025: divergence, with US and European guidance moving lower than WHO/ISH and NICE.
Knowledge check
What explains much of the long-term trend in hypertension guidelines?
Module 2
Current guidelines do not say exactly the same thing
Guideline body
Diagnostic frame
Teaching point
ACC/AHA
Hypertension begins at 130/80 mm Hg.
Uses lower diagnostic threshold and risk-based treatment decisions; newer guidance encourages lower achieved SBP when appropriate.
ESC/ESH
Historically keeps 140/90 mm Hg diagnostic threshold.
Recent European guidance also pursues lower treatment targets in many patients and uses risk stratification.
WHO/ISH
Generally retains 140/90 mm Hg diagnostic threshold.
Emphasizes practical global implementation and risk-based treatment, with less aggressive general-population targets.
NICE
Generally retains 140/90 mm Hg diagnostic threshold.
Uses cost-effectiveness and UK practice considerations, including concern about measurement methods and implementation.
The historical review found that the largest current tension is not whether high BP matters. It is how low to define, treat, and target BP in lower-risk patients, given different interpretations of trials, health systems, measurement practices, and evidence grading.
EvidenceSPRINT and other trials
MeasurementOffice, standardized, home, ambulatory
PopulationAge, CKD, diabetes, CVD risk
SystemCost, access, feasibility, policy
Module 3
Practical 2025 updates
Lower the target
For many patients with hypertension, the message is stronger: achieve at least below 130 mm Hg systolic when indicated, and consider lower systolic goals when appropriate and tolerated.
Treat earlier
Stage 1 hypertension that does not respond to lifestyle change within a few months may move to medication, even in lower-risk patients; diabetes or CKD strengthens the case for earlier treatment.
Use combination therapy
For stage 2 hypertension, starting with combination BP-lowering therapy, often as a single-pill combination, may reach and maintain targets faster than monotherapy.
PREVENTThe newer AHA risk calculator replaces pooled cohort equations in the update and incorporates kidney function and heart failure risk.
CognitionLowering systolic BP below 130 mm Hg is framed as part of preventing mild cognitive impairment and dementia.
MeasurementDo not declare target achievement from one number; use repeated readings across visits or validated out-of-office measurement.
Knowledge check
What changed in the 2025 update for many lower-risk stage 1 hypertension patients?
Module 4
Workup, kidney risk, and secondary hypertension
Confirm the pressure
Use proper technique and repeated measurements. Decisions should not rest on a single reading when the clinical situation allows confirmation.
Look for early kidney disease
The JAMA summary highlights urine albumin-to-creatinine ratio as part of the standard workup for people with high BP, adding sensitivity beyond serum creatinine alone.
Screen more for aldosteronism
Primary aldosteronism is more common than historically recognized. Screening is emphasized for resistant hypertension, obstructive sleep apnea, and other risk patterns, and may be considered in stage 2 hypertension.
Stage 1 + low riskLifestyle first, reassess
Diabetes or CKDEarlier medication
Stage 2Often combination therapy
Resistant HTN or OSAConsider aldosteronism screen
Screening is not just about assigning a label. The point is to detect treatable drivers of risk, identify kidney involvement earlier, and choose targets and therapy intensity that match the patient.
Module 5
Prevention and counseling
The newer guidance puts more emphasis on preventing hypertension, not only treating it after diagnosis.
Counseling should be specific enough to act on and careful enough to respect kidney disease, medication tolerance, and patient goals.
Dietary sodium reduction is recommended broadly, with an ideal target lower than the standard upper limit when feasible.
Potassium-enriched salt substitutes may help many adults but are not appropriate for some patients, especially those with CKD or potassium risk.
For adults with overweight or obesity, at least 5% body-weight loss or BMI reduction may meaningfully lower BP.
GLP-1 receptor agonists may support BP reduction when used for weight management.
The update frames no alcohol intake as ideal for preventing or managing high BP; for those who drink, reducing intake still helps.
Shared decision-making
More intensive BP lowering can reduce cardiovascular, kidney, and brain risk, but therapy should be individualized for adverse effects, frailty, kidney function, orthostasis, burden, and patient preference.
MeasureConfirm BP accurately
RiskUse PREVENT and comorbidities
LifestyleSodium, weight, exercise, alcohol
TreatStart early enough, intensify safely
FollowTrack target, tolerance, labs
Final Exam
Check understanding
Passing score is 80%. A printable credential appears after a passing attempt.